Double maintains 1 strategies that include GYRE - Gyre Therapeutics, Inc.
Finnhub
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for...
Yahoo
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the “Board”) as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a m
Yahoo
Gyre Therapeutics ( NASDAQ:GYRE ) Third Quarter 2024 Results Key Financial Results Revenue: US$25.5m (down 17% from 3Q...
Yahoo
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYR
Finnhub
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Last patient completed pivotal Phase 3 trial in CHB-associated liver...
Yahoo
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that the last patient in Gyre Pharmaceuticals’ pivotal Phase 3 trial in the People’s Republic of China (“PRC”) evaluating F351 (hydronidone) for Chronic Hepatitis B (“CHB”)-associated liver fibrosis has completed the 52-week study. Gyre Pharmaceut
Current Value
$12.041 Year Return
Current Value
$12.041 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTGC | -0.05% | $2.48B | 1.02% |
BUXX | -0.08% | $225.32M | 0.25% |
USL | -0.17% | $44.82M | 0.85% |
SPTS | 0.17% | $5.89B | 0.03% |
IBMO | -0.17% | $504.65M | 0.18% |
IBMS | -0.21% | $40.70M | 0.18% |
USO | 0.21% | $839.47M | 0.6% |
PHDG | -0.21% | $114.74M | 0.39% |
IBD | -0.29% | $381.25M | 0.44% |
BSMW | -0.32% | $101.90M | 0.18% |
CGMU | 0.32% | $2.96B | 0.27% |
SHM | 0.38% | $3.40B | 0.2% |
BNO | 0.38% | $89.45M | 1% |
UTWO | 0.40% | $376.56M | 0.15% |
OILK | 0.41% | $63.98M | 0.69% |
XHLF | -0.41% | $1.06B | 0.03% |
TBIL | -0.45% | $5.24B | 0.15% |
DBO | -0.47% | $188.24M | 0.77% |
MUNI | 0.63% | $1.80B | 0.35% |
KMLM | -0.64% | $322.65M | 0.9% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CB | 0.02% | $117.71B | +14.70% | 1.53% |
ARCO | 0.04% | $1.74B | -27.14% | 2.89% |
PM | 0.05% | $236.15B | +61.11% | 3.47% |
NEE | -0.06% | $151.29B | +22.42% | 2.89% |
BUD | -0.06% | $109.31B | +2.53% | 1.40% |
LIVN | 0.07% | $2.13B | -22.45% | 0.00% |
FSLR | -0.09% | $14.19B | -10.11% | 0.00% |
NXTC | -0.11% | $19.29M | -52.49% | 0.00% |
TMDX | -0.11% | $2.31B | -9.76% | 0.00% |
PEP | -0.14% | $203.79B | -9.76% | 3.63% |
WRB | -0.15% | $23.98B | +13.03% | 0.57% |
TW | -0.20% | $28.94B | +30.34% | 0.31% |
DV | -0.21% | $2.38B | -56.60% | 0.00% |
AMT | -0.21% | $98.60B | +6.89% | 3.05% |
EQNR | -0.22% | $66.42B | -2.32% | 5.67% |
UL | -0.22% | $147.65B | +19.96% | 3.15% |
FMS | -0.23% | $14.11B | +26.31% | 2.75% |
GO | -0.28% | $1.17B | -55.29% | 0.00% |
LEVI | 0.28% | $6.38B | -11.43% | 3.17% |
OCFT | -0.34% | $239.53M | +170.12% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACA | 36.63% | $3.94B | -1.12% | 0.25% |
PNFP | 35.08% | $7.95B | +29.50% | 0.87% |
SFBS | 34.81% | $4.55B | +35.13% | 1.49% |
RYTM | 33.79% | $3.22B | +27.42% | 0.00% |
BN | 33.67% | $82.97B | +22.93% | 0.65% |
NLOP | 33.49% | $452.13M | +32.70% | 0.00% |
SNV | 33.46% | $6.44B | +20.66% | 3.33% |
PIPR | 33.46% | $4.50B | +34.35% | 1.01% |
AMWD | 33.35% | $875.54M | -37.72% | 0.00% |
PFS | 33.35% | $2.12B | +17.79% | 5.58% |
JOE | 33.31% | $2.61B | -15.02% | 1.22% |
VBTX | 33.31% | $1.33B | +31.10% | 3.28% |
KN | 33.28% | $1.40B | +5.19% | 0.00% |
URI | 33.26% | $40.68B | -7.79% | 1.07% |
WABC | 33.23% | $1.37B | +9.77% | 3.43% |
OEC | 33.18% | $745.57M | -42.26% | 0.64% |
CLBK | 33.03% | $1.59B | -4.58% | 0.00% |
ABCB | 32.97% | $3.96B | +25.75% | 1.14% |
BXP | 32.95% | $10.36B | +4.65% | 5.88% |
SEM | 32.91% | $2.16B | +9.38% | 2.62% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -12.88% | $22.40B | +16.58% | 1.13% |
INSM | -12.31% | $13.86B | +197.63% | 0.00% |
CYCN | -11.60% | $6.86M | -22.15% | 0.00% |
GL | -11.17% | $10.52B | +8.08% | 0.77% |
SRDX | -9.20% | $404.58M | +0.46% | 0.00% |
CTMX | -8.79% | $52.03M | -68.62% | 0.00% |
FUBO | -8.65% | $1.09B | +110.60% | 0.00% |
CELH | -8.10% | $6.37B | -70.85% | 0.00% |
GHI | -8.07% | $293.35M | -23.78% | 11.61% |
MRK | -8.05% | $238.89B | -22.18% | 3.31% |
VRSK | -7.70% | $40.48B | +23.05% | 0.70% |
HLN | -7.52% | $45.95B | +22.14% | 1.54% |
FDP | -7.43% | $1.44B | +20.73% | 3.52% |
RYAN | -7.39% | $8.78B | +25.89% | 0.64% |
GRFS | -7.38% | $2.06B | +30.18% | 0.00% |
DOGZ | -7.28% | $350.22M | +196.76% | 0.00% |
STG | -6.82% | $28.14M | -46.51% | 0.00% |
GIS | -6.78% | $32.83B | -10.78% | 3.98% |
TRVG | -6.59% | $93.99M | +59.07% | 0.00% |
PG | -6.47% | $393.86B | +4.08% | 2.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -26.05% | $195.31M | 0.85% |
TAIL | -22.99% | $81.50M | 0.59% |
BTAL | -21.97% | $392.59M | 1.43% |
CTA | -10.91% | $833.97M | 0.76% |
ULST | -9.22% | $579.50M | 0.2% |
XONE | -8.07% | $620.20M | 0.03% |
TPMN | -7.70% | $33.23M | 0.65% |
TBLL | -6.24% | $2.04B | 0.08% |
USDU | -6.15% | $279.86M | 0.5% |
XBIL | -5.88% | $705.62M | 0.15% |
DUSB | -4.29% | $1.12B | 0.15% |
UNG | -4.12% | $435.14M | 1.06% |
UUP | -4.02% | $319.56M | 0.77% |
PWZ | -4.01% | $712.50M | 0.28% |
TOTL | -3.93% | $3.47B | 0.55% |
WEAT | -3.73% | $122.01M | 0.28% |
YEAR | -3.56% | $1.26B | 0.25% |
TFLO | -3.47% | $6.75B | 0.15% |
AGZ | -3.35% | $643.72M | 0.2% |
PREF | -3.19% | $1.12B | 0.55% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 53.66% | $48.94M | 0.69% |
RSPA | 46.84% | $272.02M | 0% |
QQA | 40.47% | $161.30M | 0% |
CPSJ | 40.16% | $33.88M | 0.69% |
IWC | 38.52% | $799.77M | 0.6% |
ETH | 38.35% | $1.29B | 0% |
QETH | 38.33% | $15.21M | 0.25% |
ETHW | 38.05% | $175.81M | 0% |
EZET | 38.04% | $21.77M | 0% |
FETH | 38.04% | $755.56M | 0.25% |
CETH | 38.04% | $7.85M | 0% |
ETHA | 37.95% | $2.31B | 0.25% |
ETHV | 37.90% | $87.32M | 0% |
IWN | 36.79% | $10.75B | 0.24% |
BTC | 36.44% | $3.28B | 0.15% |
GSSC | 36.28% | $498.32M | 0.2% |
VTWO | 36.28% | $10.56B | 0.07% |
IWM | 36.15% | $63.99B | 0.19% |
FYX | 36.01% | $819.81M | 0.6% |
PRFZ | 35.28% | $2.30B | 0.39% |